Indivior Pharmaceuticals (INDV) Asset Utilization Ratio (2025 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Asset Utilization Ratio of 1.08 for Q1 2026, up 23.72% year-over-year from 0.87 in Q1 2025, and up 13.62% quarter-over-quarter from 0.95 in Q4 2025.
Indivior Pharmaceuticals (INDV) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 1.08 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 23.72% year-over-year to 1.08; the TTM figure through Mar 2026 stood at 1.08 (up 23.72% YoY), while the FY2025 annual figure was 0.98, up 27.37% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 1.08, up from 0.95 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 1.08 in Q1 2026, with the low at 0.82 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 0.43 |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 0.63 |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 0.47 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 0.45 |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.41 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 0.66 |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 0.37 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Indivior Pharmaceuticals | 4.51 Bn | 4.29 Bn | 294.00 Mn | 1.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 |
| Mar 31, 2026 | 1.08 |
| Dec 31, 2025 | 0.95 |
| Sep 30, 2025 | 0.82 |
| Jun 30, 2025 | 0.83 |
| Mar 31, 2025 | 0.87 |